All four patients with an RCC profile received tyrosine-kinase inhibitor, while five received immune checkpoint inhibitor (ICI) as first-line therapy (two with melanoma of unknown primary profile, one with a GSPC profile with high microsatellite instability (MSI), and two with NSCLC and UtCC profiles with high programmed cell deth1-ligand1 (PD-L1) tumor proportion score (TPS). The gene discussed is CD274; the disease is renal cell adenocarcinoma.